Literature DB >> 16435096

[Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].

M Krismann1, P Thattamparambil, F Simon, G Johnen.   

Abstract

The morphological diagnosis of small mesothelial lesions in pleural biopsies is gaining importance in view of more aggressive, multimodal therapeutic options and of medicolegal aspects if a malignant mesothelioma is diagnosed. We present a light microscopically and immunohistochemically based morphological classification for the planning of further clinical follow-up procedures. A reactive mesothelial hyperplasia heals without scars. Mesothelial inclusions in pleuritic scars are common in recurrent pleuritis and must not be confused with an epithelioid component of a desmoplastic mesothelioma. In case of atypical mesothelial proliferations, further diagnostic procedures have to be performed to obtain a clear diagnosis of malignancy. Mesothelioma in situ is the first morphological step in neoplastic mesothelial changes, also with regard to medicolegal aspects for the unambiguous diagnosis of a mesothelioma. Early infiltrative growth is characteristic of so called early mesothelioma. A useful immunohistochemical panel for the differential diagnosis consists of anti-cytokeratin, Ck 5/6, calretinin, EMA and MiB-1, whereas the immunohistochemical detection of telomerase is not helpful.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16435096     DOI: 10.1007/s00292-005-0815-9

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  7 in total

1.  The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.

Authors:  P M Cury; D N Butcher; B Corrin; A G Nicholson
Journal:  J Pathol       Date:  1999-10       Impact factor: 7.996

2.  Chromosomal alterations in early stages of malignant mesotheliomas.

Authors:  Frank Simon; Georg Johnen; Michael Krismann; Klaus-Michael Müller
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

3.  Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas.

Authors:  Fumiyuki Kumaki; Toshiaki Kawai; Andrew Churg; Françoise B Galateau-Sallé; Philip Hasleton; Douglas Henderson; Victor Roggli; William D Travis; Philip T Cagle; Victor J Ferrans
Journal:  Am J Surg Pathol       Date:  2002-03       Impact factor: 6.394

Review 4.  Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.

Authors:  D W Henderson; K B Shilkin; D Whitaker
Journal:  Am J Clin Pathol       Date:  1998-09       Impact factor: 2.493

5.  The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.

Authors:  R L Attanoos; A Griffin; A R Gibbs
Journal:  Histopathology       Date:  2003-09       Impact factor: 5.087

6.  Epithelial Membrane Antigen. Its use in the cytodiagnosis of malignancy in serous effusions.

Authors:  A To; D P Dearnaley; M G Ormerod; G Canti; D V Coleman
Journal:  Am J Clin Pathol       Date:  1982-08       Impact factor: 2.493

7.  Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases.

Authors:  Michael Krismann; Klaus-Michael Müller; Malgorzata Jaworska; Georg Johnen
Journal:  J Pathol       Date:  2002-07       Impact factor: 7.996

  7 in total
  1 in total

Review 1.  [Morphological diagnostics of malignant pleural mesothelioma].

Authors:  K Junker; K-M Müller
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.